[go: up one dir, main page]

AR065803A1 - Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento - Google Patents

Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento

Info

Publication number
AR065803A1
AR065803A1 ARP080101155A ARP080101155A AR065803A1 AR 065803 A1 AR065803 A1 AR 065803A1 AR P080101155 A ARP080101155 A AR P080101155A AR P080101155 A ARP080101155 A AR P080101155A AR 065803 A1 AR065803 A1 AR 065803A1
Authority
AR
Argentina
Prior art keywords
lymphoma
cell
leukemia
hodgkin
cells
Prior art date
Application number
ARP080101155A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39788932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065803(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR065803A1 publication Critical patent/AR065803A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de (i) un polipéptido de IL-18 humana (SEQ ID N°:16); y (ii) un anticuerpo anti-CD, tal como rituximab u ofatumumab para preparar un medicamento util para tratar o prevenir cánceres para uso simultáneo o secuencial en cualquier orden. El cáncerse selecciona entre el grupo consistente en NHL (linfoma no Hodgkin), incluyendo leucemia linfoblástica de células B/linfoma, neoplasmas de células B maduras, leucemia Iinfocítica cronica da células B (CLL)/Iinfoma linfocítico pequeno (SLL),leucemia proIinfocítica de células B, linfoma linfoplasmacítico, linfoma de células del manto (MCL), linfoma folicuIar (FL), incluyendo FL de bajo grado, de grado intermedio y de alto grado, linfoma del centro folicular cutáneo, linfoma de células Bde zona marginal (tipo MALT, tipo nodal y esplénico), leucemia de células pilosas, linfoma de células B grande difuso, linfoma de Burkitt, plasmacitoma, mieloma de células plasmáticas, trastorno linfoproliferativo posterior a un trasplante,macroglobulinemia de Waldenstrom linfoma anaplásico de células grandes (ALCL), y linfoma no Hodgkin de células T.
ARP080101155A 2007-03-23 2008-03-19 Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento AR065803A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89685507P 2007-03-23 2007-03-23
US95200207P 2007-07-26 2007-07-26

Publications (1)

Publication Number Publication Date
AR065803A1 true AR065803A1 (es) 2009-07-01

Family

ID=39788932

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080101155A AR065803A1 (es) 2007-03-23 2008-03-19 Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
ARP080101195A AR065818A1 (es) 2007-03-23 2008-03-25 Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humana

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP080101195A AR065818A1 (es) 2007-03-23 2008-03-25 Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humana

Country Status (21)

Country Link
US (4) US20100111945A1 (es)
EP (3) EP2129398A4 (es)
JP (2) JP2010522239A (es)
KR (2) KR20100015798A (es)
CN (1) CN101678102A (es)
AR (2) AR065803A1 (es)
AU (2) AU2008231025A1 (es)
BR (2) BRPI0808943A2 (es)
CA (2) CA2681851A1 (es)
CL (2) CL2008000818A1 (es)
CR (2) CR10996A (es)
DO (2) DOP2009000208A (es)
EA (2) EA200970884A1 (es)
IL (2) IL200525A0 (es)
MA (2) MA31264B1 (es)
MX (2) MX2009010269A (es)
NZ (1) NZ579179A (es)
PE (2) PE20090190A1 (es)
SG (1) SG171674A1 (es)
TW (2) TW200906436A (es)
WO (2) WO2008118733A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
UA120364C2 (uk) 2014-04-25 2019-11-25 Пьєр Фабр Медікамент Кон'югат антитіла до igf-1r з лікарським засобом
PL3134125T3 (pl) 2014-04-25 2020-04-30 Pierre Fabre Médicament Koniugat przeciwciało-lek i jego zastosowanie do leczenia raka
CN106687124B (zh) * 2014-08-07 2022-03-15 冈村春树 并用il-18与分子靶向抗体的癌治疗药
WO2016126615A1 (en) * 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20240368247A1 (en) * 2020-12-02 2024-11-07 The Royal Institution For The Advancement Of Learning/Mcgill University Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists
WO2025033330A1 (ja) * 2023-08-04 2025-02-13 医療革新国際連携株式会社 キマーゼ阻害剤と免疫療法の併用による抗腫瘍療法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
TW464656B (en) 1994-11-15 2001-11-21 Hayashibara Biochem Lab Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease
US5680795A (en) 1995-07-05 1997-10-28 Norco Inc. Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
JP5121109B2 (ja) 2000-06-15 2013-01-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 生理的に活性なｉｌ−１８ポリペプチドの調製方法
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
CN1646161A (zh) * 2002-02-21 2005-07-27 杜克大学 自身免疫疾病的药剂和治疗方法
SI2298338T1 (sl) * 2002-09-16 2012-11-30 Agennix Inc Laktoferinski sestavki in postopki za zdravljenjekožnih ran
CN101658672B (zh) * 2002-10-08 2017-09-26 免疫医疗公司 用iii类抗cea单克隆抗体和治疗剂进行联合治疗
WO2004035607A2 (en) * 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP1613274B1 (en) * 2003-04-15 2010-03-03 GlaxoSmithKline LLC Human il-18 substitution mutants and their conjugates
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
EP1648512A4 (en) * 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
ATE497975T1 (de) * 2005-04-18 2011-02-15 Novo Nordisk As Il-21-varianten
KR20080030673A (ko) * 2005-07-21 2008-04-04 젠맵 에이/에스 Ｆｃ 수용체와 결합하는 항체 약품 성분에 대한 효력 검정
AU2007272330A1 (en) * 2006-07-13 2008-01-17 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
CA2662609A1 (en) * 2006-09-14 2008-03-20 The Trustees Of The University Of Pennsylvania Modulation of regulatory t cells by human il-18
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento

Also Published As

Publication number Publication date
WO2008118736A1 (en) 2008-10-02
CN101678102A (zh) 2010-03-24
DOP2009000208A (es) 2010-03-31
US20100196310A1 (en) 2010-08-05
NZ579179A (en) 2011-12-22
IL200863A0 (en) 2010-05-17
AU2008231025A1 (en) 2008-10-02
EP2129398A1 (en) 2009-12-09
KR20100015798A (ko) 2010-02-12
AU2008231114A1 (en) 2008-10-02
EA200970885A1 (ru) 2010-02-26
EP2136841A4 (en) 2010-07-07
CR11075A (es) 2010-03-22
WO2008118733A2 (en) 2008-10-02
BRPI0808943A2 (pt) 2014-08-26
CA2681827A1 (en) 2008-10-02
WO2008118733A3 (en) 2008-11-27
IL200525A0 (en) 2010-04-29
US20080274078A1 (en) 2008-11-06
TW200904469A (en) 2009-02-01
BRPI0809079A2 (pt) 2019-03-06
JP2010522239A (ja) 2010-07-01
EP2129398A4 (en) 2010-04-21
CR10996A (es) 2009-11-12
PE20090190A1 (es) 2009-03-22
CL2008000818A1 (es) 2008-09-26
SG171674A1 (en) 2011-06-29
DOP2009000220A (es) 2009-10-31
MX2009010269A (es) 2009-10-12
PE20090184A1 (es) 2009-03-22
MX2009010271A (es) 2009-10-12
US20090035258A1 (en) 2009-02-05
EP2338514A1 (en) 2011-06-29
MA31265B1 (fr) 2010-03-01
AR065818A1 (es) 2009-07-01
JP2010522200A (ja) 2010-07-01
KR20100014530A (ko) 2010-02-10
US20100111945A1 (en) 2010-05-06
EA200970884A1 (ru) 2010-04-30
EP2136841A2 (en) 2009-12-30
MA31264B1 (fr) 2010-03-01
CA2681851A1 (en) 2008-10-02
CL2008000842A1 (es) 2008-10-17
TW200906436A (en) 2009-02-16

Similar Documents

Publication Publication Date Title
AR065803A1 (es) Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
CY1120707T1 (el) Anti-cd28 εξανθρωπισμενα αντισωματα
BR112013002079A2 (pt) modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer
CL2012002733A1 (es) Compuestos derivados de ácido 1-amino-2-ciclopropiletilborónico, inhibidores de proteasoma; composición farmacéutica; uso en el tratamiento del cáncer; procedimiento de preparacion; compuestos intermediarios.
UY34077A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
EP4530630A3 (en) Monoclonal antibodies and methods of use
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
MX370148B (es) Composiciones y su uso para inmunoterapia.
CR9518A (es) Eliminacion de poblacion celular heterogenea o mezclada en tumores
BR112019021857A2 (pt) Métodos e composições de célula t aperfeiçoada
EA201391351A1 (ru) Способы повышения эффективности folr1 терапии рака
AR068818A1 (es) Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit
CL2012001387A1 (es) Anticuerpos murinos, humanizados o fragmentos de ellos anti-receptor epha2; conjugados citotoxicos; composiciones farmaceuticas que los contienen; secuencias nucleotidicas; vector; celula huesped e hibridomas que los producen y el uso de los anticuerpos en el tratamiento del cancer como en metodos de diagnostico. (divisional de sol. n° 2085-07)
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
BR112013005145A2 (pt) anticorpos anti-cxcl13 e métodos para seu uso
AR080154A1 (es) Anticuerpos cd20 y su utilizacion
GT201300046A (es) Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3)
PE20151780A1 (es) Uso de 2 - 3 dihidroimidazo[ 1,2- c] quinazolinas sustituidas
MX2020011527A (es) Terapia de combinación de una terapia de células t-receptor de antígeno quimérico (car) y un inhibidor de cinasa.
PE20131111A1 (es) Clasificacion de material extraido
EP2614051A4 (en) P53-MDM2 ANTAGONISTS
SV2011003891A (es) Antagonistas de los receptores tipo toll 3
ECSP11011172A (es) Derivados de tieno [3,2-c]piridina como inhibidores de quinasas para el uso en el tratamiento del cáncer.
UY33349A (es) Nuevos compuestos de quinoxalina, quinolina y quinazolina, composiciones farmacéuticas que los contienen y uso de los mismos
AR083751A1 (es) Derivados de 1h-pirrolo[2,3-b]piridina y uso de los mismos en el tratamiento del cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal